TY  - GEN
AU  - Itzykson,Raphael
AU  - Thépot,Sylvain
AU  - Quesnel,Bruno
AU  - Dreyfus,Francois
AU  - Beyne-Rauzy,Odile
AU  - Turlure,Pascal
AU  - Vey,Norbert
AU  - Recher,Christian
AU  - Dartigeas,Caroline
AU  - Legros,Laurence
AU  - Delaunay,Jacques
AU  - Salanoubat,Célia
AU  - Visanica,Sorin
AU  - Stamatoullas,Aspasia
AU  - Isnard,Francoise
AU  - Marfaing-Koka,Anne
AU  - de Botton,Stephane
AU  - Chelghoum,Youcef
AU  - Taksin,Anne-Laure
AU  - Plantier,Isabelle
AU  - Ame,Shanti
AU  - Boehrer,Simone
AU  - Gardin,Claude
AU  - Beach,C L
AU  - Adès,Lionel
AU  - Fenaux,Pierre
TI  - Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
SN  - 1528-0020
PY  - 2011///0223
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antimetabolites, Antineoplastic
KW  - therapeutic use
KW  - Azacitidine
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Myelodysplastic Syndromes
KW  - drug therapy
KW  - Prognosis
KW  - Young Adult
N1  - Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1182/blood-2010-06-289280
ER  -